

CITATION REPORT

List of articles citing

Combination Therapy with Nusinersen and Onasemnogene Apeparvovec-xioi in Spinal Muscular Atrophy Type I

DOI: 10.3390/jcm10235540

Journal of Clinical Medicine, 2021, 10, .

Source: <https://exaly.com/paper-pdf/123195219/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy. <i>Biology</i> , 2022 , 11, 894	4.9	0
8	Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy. Volume 15, 7341-7353		0
7	Onasemnogene abeparvovec in type 1 spinal muscular atrophy: A systematic review and meta-analysis.		0
6	Clinical and Electrophysiological Changes in Pediatric Spinal Muscular Atrophy after 2 Years of Nusinersen Treatment. 2022 , 14, 2074		0
5	Nusinersen for spinal muscular atrophy types II and III: a retrospective single-center study in South Korea.		0
4	Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study. 2023 , 12, 543-557		0
3	Real world safety and exploratory efficacy of gene therapy for patients with 5q-Spinal Muscular Atrophy in a Brazilian cohort.		0
2	Real-life Outcome after Gene Replacement Therapy for Spinal Muscular Atrophy: a Multicenter Experience. 2023 ,		0
1	Redox Imbalance in Neurological Disorders in Adults and Children. 2023 , 12, 965		0